diamedica therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with the focus on neurological and kidney diseases. for more information please visit www.diamedica.com.
Company profile
Ticker
DMAC
Exchange
Website
CEO
Rick John Pauls
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DiaMedica Inc.
SEC CIK
Corporate docs
Subsidiaries
DiaMedica USA Inc. • DiaMedica Australia Pty Ltd. ...
DMAC stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
10 Apr 24
EFFECT
Notice of effectiveness
10 Apr 24
ARS
2023 FY
Annual report to shareholders
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
S-3
Shelf registration
21 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
19 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
13 Nov 23
Transcripts
DMAC
Earnings call transcript
2023 Q3
14 Nov 23
DMAC
Earnings call transcript
2023 Q2
15 Aug 23
DMAC
Earnings call transcript
2023 Q1
16 May 23
DMAC
Earnings call transcript
2022 Q4
29 Mar 23
DMAC
Earnings call transcript
2022 Q2
11 Aug 22
DMAC
Earnings call transcript
2022 Q1
7 May 22
DMAC
Earnings call transcript
2021 Q4
15 Mar 22
DMAC
Earnings call transcript
2021 Q3
11 Nov 21
DMAC
Earnings call transcript
2021 Q2
12 Aug 21
DMAC
Earnings call transcript
2021 Q1
9 May 21
Latest ownership filings
4
Masuoka K. Lorianne
23 Jan 24
3
Masuoka K. Lorianne
23 Jan 24
4
Charles Pauling Semba
2 Jan 24
4
Richard Kuntz
2 Jan 24
4
Richard D. Pilnik
2 Jan 24
4
James T. Parsons
2 Jan 24
4
Randall Michael Giuffre
2 Jan 24
4
David J. Wambeke
16 Nov 23
SC 13G/A
TomEnterprise AB
27 Jun 23
SC 13G/A
TRILL AB
27 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.23 mm | 2.23 mm | 2.23 mm | 2.23 mm | 2.23 mm | 2.23 mm |
Cash burn (monthly) | 1.20 mm | 44.92 k | 1.72 mm | 1.62 mm | 1.60 mm | 1.47 mm |
Cash used (since last report) | 8.17 mm | 305.39 k | 11.69 mm | 10.99 mm | 10.87 mm | 10.02 mm |
Cash remaining | -5.94 mm | 1.93 mm | -9.46 mm | -8.76 mm | -8.64 mm | -7.79 mm |
Runway (months of cash) | -4.9 | 42.9 | -5.5 | -5.4 | -5.4 | -5.3 |
Institutional ownership, Q2 2023
41.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 9 |
Closed positions | 2 |
Increased positions | 9 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 15.12 bn |
Total shares | 15.62 mm |
Total puts | 200.00 |
Total calls | 17.20 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
TomEnterprise AB | 4.33 mm | $18.39 mm |
Trill Ab | 4.02 mm | $17.09 mm |
Private AB TomEqt | 2.86 mm | $3.86 mm |
Xiao Zhenyu | 929.71 k | $6.37 mm |
Cooperman Leon G | 875.99 k | $3.78 bn |
Vanguard | 782.99 k | $3.38 bn |
Paragon Associates & Paragon Associates Ii Joint Venture | 325.00 k | $1.40 bn |
Bleichroeder | 294.12 k | $1.27 bn |
EAM Investors | 270.42 k | $1.17 bn |
Jacob Asset Management Of New York | 198.73 k | $858.51 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Jan 24 | Masuoka K. Lorianne | Stock option Common Shares | Grant | Acquire A | No | No | 2.79 | 285,000 | 795.15 k | 285,000 |
2 Jan 24 | Giuffre Randall Michael | Voting Common Shares, no par value per share | Grant | Acquire A | No | No | 2.8 | 19,196 | 53.75 k | 364,551 |
2 Jan 24 | Parsons James T. | Voting Common Shares, no par value per share | Grant | Acquire A | No | No | 2.8 | 21,428 | 60.00 k | 59,937 |
2 Jan 24 | Pilnik Richard D. | Voting Common Shares, no par value per share | Grant | Acquire A | No | No | 2.8 | 30,357 | 85.00 k | 278,602 |
News
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $8
21 Mar 24
Oppenheimer Reiterates Outperform on DiaMedica Therapeutics, Lowers Price Target to $6
21 Mar 24
Recap: DiaMedica Therapeutics Q4 Earnings
19 Mar 24
DiaMedica Therapeutics FY23 EPS $(0.60) Vs $(0.52) YoY; $53M Cash With Runway To 2026
19 Mar 24